Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma

We report a Japanese patient with HIV-associated Kaposi sarcoma (KS) who had many cutaneous KS lesions with extensive bilateral groin edema. As the KS was refractory to antiretroviral therapy and pegylated liposomal doxorubicin (PLD), he was administered PLD up to a cumulative dose of 940 mg/m2 in 1...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2020-02, Vol.26 (2), p.289-291
Main Authors: Yokota, Kazuhisa, Yotsumoto, Mihoko, Muramatsu, Takashi, Saito, Masuyoshi, Kamikubo, Yoshiko, Ichiki, Akito, Chikasawa, Yushi, Bingo, Masato, Hagiwara, Takeshi, Amano, Kagehiro, Fukutake, Katsuyuki
Format: Article
Language:English
Subjects:
HIV
Kaposi sarcoma
Pegylated liposomal doxorubicin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a Japanese patient with HIV-associated Kaposi sarcoma (KS) who had many cutaneous KS lesions with extensive bilateral groin edema. As the KS was refractory to antiretroviral therapy and pegylated liposomal doxorubicin (PLD), he was administered PLD up to a cumulative dose of 940 mg/m2 in 10 years, which exceeded the recommended lifetime dose (550 mg/m2). However, the patient showed no major adverse events, including cardiotoxicity, and he eventually died of pancreatic cancer.
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2019.08.016